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Background: Menopause is a natural phase in a woman’s aging process, characterized by the cessation of
menstruation. Women who are going through the menopause transition can experience physiological symptoms
that significantly impact their quality of life. Concern about adverse effects of traditional hormone therapy often
leads women to purchase over-the-counter (OTC) natural health products (NHPs). The goal of this study was to
investigate the range of OTC NHPs for menopause available to Canadian women, and the packaging information
they can access to make self-management decisions.
Methods: Edmonton stores belonging to each of nine Canadian pharmacy chains were visited to identify NHPs
marketed for the relief of menopausal symptoms. Details were extracted from the packaging: a) product name
and manufacturer, b) Health Canada license number, c) medically active ingredients, d) claims of efficacy, e)
contra-indications and warnings, and f) daily cost. Data were entered and analyzed using Microsoft Excel.
Results: We identified 20 OTC NHP menopausal products, 19 of which had Health Canada license numbers. Twenty-
eight medically active ingredients were identified, with the most common being black cohosh (in 14 products) and
soy isoflavones (n = 7), chaste tree (n = 5), and dong quai (n = 3). Most products claimed they would relieve vasomotor
symptoms, including hot flashes (n = 14) and night sweats (n = 10). Each product had a labeled contraindication for at
least one specific condition. Costs per recommended daily dose ranged from $0.07 to a maximum of $2.50 (CAD$).
Conclusion: Natural health products for menopausal symptoms are easily available to Canadian women. The lack of
clear evidence of product efficacy makes the need for easily accessible, balanced information on this topic important
for women to make well informed choices.
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Menopause is a natural phase in a woman’s aging process
characterized by the cessation of menstruation. The ma-
jority of women experience physiological symptoms that
significantly impact their quality of life. The most com-
mon symptoms reported are hot flashes and night sweats,
with 50-85% of perimenopausal women experiencing
vasomotor instability [1]. Depressed mood, urogenital
changes, and sleep disturbances are other symptoms* Correspondence: bsydora@ualberta.ca
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unless otherwise stated.commonly experienced by women during menopause [2].
While traditional hormone therapy has been found to be
approximately 90% effective in reducing vasomotor symp-
toms [3], results of clinical trials implicating the therapy in
the increased risk of cardiac events, strokes, and breast
cancer [4-6] have caused women to seek alternative rem-
edies for menopausal symptoms. Women wish to be ac-
tively involved in their choice of alternative treatments [7].
Canadian surveys suggest that as many as 60 to 90% of
women may consider taking complementary and/or alter-
native medicine for menopause symptoms [8,9], but are
concerned about obtaining credible advice and the cost of
alternative treatments [7].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Canada for sale over-the-counter (OTC) without a pre-
scription include vitamins, minerals, herbal remedies,
and homeopathic medicines. All NHPs sold in Canada
are required to have a Health Canada product license
(designated by an eight-digit Natural Product Number
(NPN)), which indicates that safety, quality, and efficacy
evidence has been assessed [10,11]. For Health Canada
licensing of NHPs, efficacy evidence is required in pro-
portional to the risk inherent in the treated condition;
for example, a NHP for treating a high risk condition
(one that is life-threatening without effective treatment)
requires strong, corroborated evidence of efficacy, while
a NHP for a low risk condition (a minor condition that
may resolve itself over time) requires less efficacy evi-
dence [10,11]. Health Canada currently approves 448
products for menopause sale consisting of single and
multiple active ingredients. While there have been stud-
ies into the effectiveness of different NHPs for treating
menopausal symptoms, opinions over the efficacy of
these products remains mixed [12-17].
Natural health products are widely available for pur-
chase in pharmacies across Canada, and pharmacies are
considered by women as a significant resource to sup-
port decision-making [7]. Our research, a survey of
NHPs sold in Canadian pharmacies, set out to identify
both the range of OTC products that are available for
women who are seeking non-hormonal alternatives for
relief of their menopause symptoms, and the informa-
tion available on product packaging to help them make
their self-management decisions.
Methods
Our descriptive study was a survey of OTC NHPs that
are available to woman seeking OTC relief for meno-
pausal symptoms in Canada-wide pharmacies in a single
city, Edmonton.
Pharmacy selection
We included nine pharmacy chains with retail stores in
Edmonton, Alberta, selected to include a range of retail
types (specialized pharmacy chain, grocery or depart-
ment stores with in-house pharmacies). Only chains
with retail stores in four or more Canadian provinces or
territories were included in our study. In June 2014, one
location for each of the nine pharmacy chains was vis-
ited in order to provide a snapshot of the available NHPs
for menopause. The identity and availability of relevant
products was initially documented in-store in June 2014.
Product selection
Natural health products and OTC remedies were included
if the product information found on the packaging stated
that its recommended use was for menopause symptoms(solely or among others). Products that claimed relief for
other symptoms that may be seen in menopause (i.e. sleep,
anxiety) but did not specifically mention “menopause”
were excluded. The name, manufacturer and NPN for
each product were noted. One container of each product
identified was purchased.
Data extraction
The following data items that women might consider
when selecting a NHP were collected from the pack-
aging for each individual product:
 Name and quantity of each active ingredient in the
product
 Recommended indications of the product
 Contraindications and warnings of the product
 Recommended daily dose for each product
 Cost per package (CAD$)
Data analysis
All data were entered into a Microsoft Excel spreadsheet
to categorize product and ingredient data.
Cost per recommended daily dose was calculated for
each product for each store where it was identified by
dividing the retail price by the number of tablets or cap-
sules sold and multiplying by the average recommended
daily dose as stated on the product’s package. The range
of costs per daily dose is presented for products sold in
more than one store at different retail prices.
Excel’s statistical analysis tools were used to calculate




In the nine selected Canadian pharmacy chains we iden-
tified and purchased a total of 20 OTC NHPs available
for relief of menopausal symptoms between 13 October
and 18 November 2014. The median number of prod-
ucts available per pharmacy was eight, with a range of
two to 12 products. Details of the individual products
are described in Tables 1 and 2.
Regulatory approval
Nineteen of the products were labeled with an NPN
(Table 1). One product had no available information re-
garding its regulatory approval. Three of the black cohosh
products had the same NPN, indicating that each of these
store “own brand” products were made under license by
the same manufacturer, in this case WN Pharmaceuticals.
Ingredients
A total of 28 different active ingredients were identified.
The number of active ingredients per product varied
Table 1 Details of the product, active ingredients, daily dose and cost per dose





Ingredients active for menopause symptoms,
amount per tablet 5 most common active
ingredients in bold
Recommended
daily dose (# of
tablets, frequency)




Swiss Natural HRT® Regular/
Valeant Canada LP/S.E.C.
80038543 Black cohosh (30 mg), chaste tree (100 mg),
soy isoflavones (70 mg), wild yam (50 mg),
burdock (50 mg)
1, twice daily $0.36-$0.93
Swiss Natural HRT® Extra
Strength/Valeant Canada
LP/S.E.C.
80019270 Black cohosh (100 mg), chaste tree (200 mg),
soy isoflavones (100 mg), wild yam (50 mg),
burdock (100 mg)
1, daily $0.18-$0.47
Swiss Natural HRT® Nightime/
Valeant Canada LP/S.E.C.
80002152 Black cohosh (100 mg), lemon balm (300 mg),
passion flower (150 mg)
1, at night $0.36-$0.47
Estroven®/i-Health, Inc. 80024706 Black cohosh (40 mg), soy isoflavones (37.5 mg),
calcium (150 mg), folic acid (400 μg), kudzu (100 mg),
magnolia (15 mg), vitamin E (30 IU), thiamin (2 mg),
riboflavin (2 mg), niacinamide (20 mg), vitamin B6
(10 mg), vitamin B12 (6 μg), selenium (70 μg), boron




80032569 Black cohosh (80 mg), calcium (138 mg), chaste tree
(75 mg), folic acid (400 μg), green tea (60 mg), soy
isoflavones (102.5 mg), vitamin D3 (25 μg), vitamin E
(30 IU), thiamin (5 mg), riboflavin (5 mg), niacinamide
(20 mg), vitamin B6 (20 mg), vitamin B12 (25 μg),
selenium (70 μg), boron glycinate (1.5 mg), chromium







Black cohosh (20 mg), red clover isoflavones




80025767 Black cohosh (40 mg), dong quai (125 mg),
pomegranate (75 mg), damiana (75 mg), partridge
berry (75 mg), motherwort (50 mg), schizandra
(50 mg)





80046012 Black cohosh (80 mg), chaste tree (80 mg), dong
quai (100 mg), gamma-oryzanol (75 mg), hesperidin
(30 mg)




80025898 Black cohosh (80 mg), chaste tree (80 mg), dong
quai (100 mg), gamma-oryzanol (75 mg), hesperidin









Ingredients active for menopause
symptoms, amount per tablet
Recommended








80007421b Black cohosh (40 mg) 1-2, daily $0.24
London Naturals® Black Cohosh/
WN Pharmaceuticals Ltd.
80007421b Black cohosh (40 mg) 1-2, daily $0.27
equate® Black Cohosh/Vita
Health Products Inc.
02238871 Black cohosh (40 mg) 1, daily $0.12
Holista® Black Cohosh/
Holista Health (Canada) Inc.
80010287 Black cohosh (40 mg) 1-2, daily $0.07-$0.09
Be.better™ Black Cohosh/WN
Pharmaceuticals Ltd.
80007421b Black cohosh (40 mg) 1-2, daily $0.29
Promensil® Regular Strength/
PharmaCare Laboratories
80015467 Red clover isoflavones (40 mg) 1, daily $0.67-$1.10
Promensil® Double Strength/
PharmaCare Laboratories
80016071 Red clover isoflavones (80 mg) 1, daily $1.23-$1.33
Croden et al. BMC Complementary and Alternative Medicine  (2015) 15:86 Page 3 of 8
Table 1 Details of the product, active ingredients, daily dose and cost per dose (Continued)
webber naturals® Soy Isoflavone
Complex/WN Pharmaceuticals Ltd.
80015647 Soy isoflavones (50 mg) 7, daily $0.77
Menoconfort Forté c/IRB Yves
Ponroy Canada Inc.
80021605 Soy isoflavones (300 mg)c 1, at night $0.55
i-Cool®/i-Health, Inc. 80033608 Synthetic soy isoflavones, genistein (30 mg) 1, daily $0.83-$0.87
A. Vogel™ Menopause/Bioforce
Canada Inc.
80034857 Sage (3400 mg) 1, 1 to 5 times daily $2.33-$2.50
Notes: aproducts without a range of daily cost were either only found in a single pharmacy or found in several pharmacies at a single price.
bproducts share the same licence number.
cMenoconfort Forté packages include a daytime NHP for “radiant skin”.
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ingredients, while eleven products contained a single ac-
tive ingredient. The most common active ingredients
were black cohosh (14 products), soy isoflavones (n = 7),
chaste tree (n = 5), dong quai (n = 3) and red clover iso-
flavones (n = 3).
Claims of efficacy and safety
In accordance with our product selection criteria every
OTC product made a menopause symptom health claim.
Fifteen of the 20 products asserted they were effective in
alleviating “general menopausal symptoms” with or with-
out specific symptom benefits. Fourteen of the 20 prod-
ucts claimed relief from vasomotor symptoms (Table 2),
specifically hot flashes (n = 14) and night sweats (n = 10).
One product claimed relief from urogenital symptoms,
including vaginal dryness and low libido (Table 2). Four
products claimed they would contribute to reduced bone
loss if taken with sufficient Vitamin D and calcium
(Table 2).
Each product had labeled contraindications for at
least one specific condition. There was considerable
overlap between contraindications reported, even
though the active ingredients were different (Table 2).
Eighteen of the NHPs warned against the use of the
product with liver dysfunction and 17 warned against
their use while pregnant or breastfeeding. Many of the
products had a labeled contraindication involving the
use of the product with blood thinning medications (n
= 9) or hormone replacement therapy (n = 10). Other
frequent contraindications included the use of the
product with hormone-associated gynecological disor-
ders such as endometriosis or cancers (n = 10) or his-
tory of or current breast cancer (n = 10). Warnings
were usually about stopping taking the product in the
event of new-onset liver symptoms or breast pain, or
development of an allergy to any of the ingredients.
Cost
The cost of the average recommended daily dose
(CAD$) for each product varied widely, from a mini-
mum of $0.07 to a maximum of $2.50 (Table 1). Thecost of the recommended daily dose of single ingredient
products on average (mean (SD) $0.71 (±$0.53)) was
found to be identical to, but vary more than, the average
daily cost of combination products ($0.71 (+$0.30)). Sale
prices were responsible for some products being sold at
bargain prices.
Discussion
Our investigation revealed that Canadian pharmacy
chains sold a variety of NHPs that claim they can pro-
vide relief from menopausal symptoms. Our study aimed
to be as relevant as possible to the experience of women
throughout Canada seeking over-the-counter assistance
through the menopause transition. We explored the
packaging information easily available to women making
decisions in pharmacies about which menopause-related
NHP to use. The descriptions of indications for use and
contraindications are remarkably similar between the
menopause treatments and therefore the cost of treat-
ment becomes an important factor. According to our
findings, the annual cost of purchasing OTC NHPs for
menopausal symptoms can range from $29.20 to
$872.35 (CAD$) for the average Canadian woman.
Natural health products available OTC for menopausal
symptoms are assessed and licensed on the basis of
safety and efficacy as per Health Canada’s regulation
standards. However, while Health Canada requires evi-
dence of the association of active ingredients with the
health claim made by the product, the type and amount
of evidence required depends directly on the health im-
pact on consumers if the product does not work as ex-
pected. Menopause is considered a low-risk condition by
Health Canada, in that symptoms are not life threaten-
ing and have the potential to resolve themselves over
time [10], and Health Canada requires minimal efficacy
evidence for natural health products in the low-risk cat-
egory [11]. The Health Canada regulations stipulate that
the details provided on the labels of licensed NHPs must
include information on risks and possible interactions
with conventional treatments. Furthermore, Health
Canada requires that all NHP manufacturers have a site
license, signifying that the site is able to maintain proper





















Products with multiple active ingredients
Swiss Natural HRT®
Regular
+ + - - - + + + + + + +
Swiss Natural HRT®
Extra Strength
+ + - - - + + + + + - + Diabetes
Swiss Natural HRT®
Nightime
+ + + - - + - - + + - - Avoid
alcohol/
sedatives
Estroven® + + - - - + + + + + + +
Estroven® Maximum
Strength
+ + - - Bone health + + + + + - +
Life Brand™
Menopause Relief




+ + + + - + - - + - - +
FemmeCalm Menopause
Formula
+ + + + - + + + + + + +
MENOsmart™ + + - - - + - - - - + -
Products with single active ingredient
up&up™ Black Cohosh + - - - + - - + - - - ’
London Naturals®
Black Cohosh
+ - - - + - - + - - -
equate® Black Cohosh + - - - + - - + + - - May cause
drowsiness
Holista® Black Cohosh + - - - + - - + - - -
Be.better™ Black Cohosh + - - - + - - + - - -
Promensil® Regular
Strength
+ + - - Bone & heart
health
+ + + + + + +
Promensil® Double
Strength
+ + + + Bone & heart
health, vaginal
dryness
+ + + + + + +
Soy Isoflavone Complex + + - - Bone health - + + + - + +
Menoconfort Forté + + - - - + + + - + +
xi-Cool® + + - - - + + + - + -
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products made there [18]. Health Canada rules on com-
pliance with labeling [19] ensure that the proper proto-
col for labeling is being followed and the necessary
information is being provided to consumers. However,
the volume of mandatory information means that the la-
bels use very small font sizes in order to provide the de-
tails in two languages, making the warnings inaccessible
to anyone with poor eyesight or lack of understanding of
the terms used. Potential purchasers might find informa-
tion about warnings of possible risks unsettling [20] and
seek additional information from pharmacists who must
be prepared to answer detailed questions about the
NHPs [21].
There have been many studies assessing NHP supple-
mentation for relief of menopausal symptoms [for ex-
ample 12–17]. However, the findings have been
inconsistent, and the quality and heterogeneity of stud-
ies has reduced the number of trials that can be com-
bined in systematic reviews or meta-analyses. An
Australian systematic review carried out on OTC prod-
ucts for relief of hot flashes in menopausal women
found contradictory research evidence of NHP supple-
mentation’s effectiveness, concluding that the inconsist-
ent data did not support the use of OTC products for
menopausal symptoms [12].
Black cohosh has generated the most research interest
as a treatment for menopause symptoms, of relevance to
the results of our study which found that black cohosh
was the most commonly available active ingredient,
present in 70% of the products we identified. A 2012
Cochrane review of randomized controlled trials asses-
sing black cohosh versus placebo or other treatments
found that black cohosh did not significantly reduce hot
flashes or menopausal symptom scores, whereas hor-
mone treatment (compared to black cohosh) reduced
symptom scores significantly [13]. A 2015 extensive re-
view of effects of herbal preparations on symptom clus-
ters in menopause suggested that black cohosh had a
significant effect on hot flashes [22], but this observation
was based on qualitative review of the research, rather
than the more rigorous quantitative methods used in the
Cochrane review of randomized trials [13].
Black cohosh has been suspected of being linked to
liver disorders, although cases are rare and can seldom
be attributed directly to black cohosh [14]. Evidence on
safety of black cohosh from the Cochrane review was in-
conclusive because of inadequate reporting [13], and the
more recent review suggested that the incidence of ad-
verse effects associated with black cohosh did not differ
from those associated with placebo [22].
A Cochrane review of the evidence supporting phy-
toestrogens (including soy and red clover isoflavones)
for menopausal vasomotor symptoms produced noconclusive evidence that phytoestrogen supplementation
effectively reduced the frequency or severity of hot
flashes and night sweats [15]. A sub-group of trials com-
paring Promensil (red clover isoflavones) to placebo did
not find a significant reduction in hot flashes [15]. A re-
cent meta-analysis of the efficacy of phytoestrogens ver-
sus placebo indicated that hot flash frequency was
reduced compared to placebo, but there was not a sig-
nificant treatment effect of phytoestrogens on meno-
pause symptoms more generally [16]. In the few studies
that reported side effects, there was no significant differ-
ence between phytoestrogen and placebo [16]. A system-
atic review including chaste tree and black cohosh did
not find either was more effective than the placebo in
treating climacteric complaints [17]. Despite the lack of
supporting evidence for the effectiveness of black co-
hosh, chaste tree or isoflavones in the management of
menopause symptoms, the recently published North
American Menopause Society “recommendations for the
clinical care of midlife women” acknowledges that
women often seek out this type of treatment [23].
It is worth noting that several studies on the efficacy of
NHP supplementation mention a strong placebo response
[13,24-28] ranging from 25% [24] to 63% [28]. Thus, it
would seem that although the current literature does not
show consistent efficacy evidence of the use of natural
health products for menopause [12], women might still
find relief of their symptoms from the placebo effect.
Our sample of OTC NHPs for menopause is a “snap-
shot” of products available in pharmacy chains across
Canada. An apparent limitation to this study is that only
nine Canadian pharmaceutical chains were investigated:
between these chains, they are present in all provinces
and territories in Canada and thus our sample represents
a selection of the pharmacies where Canadian women
would likely purchase an OTC supplement for meno-
pausal symptoms. There are several other limitations of
our study method. The stores we visited were in one city
and we visited only one store per pharmacy chain. We
cannot therefore comment on geographic or between-
store variation. As well, availability does not necessarily re-
flect sales, although products that did not sell would be
unlikely to remain for long on the store shelves. Our sam-
ple of NHPs represents the type and distribution of the
448 NHPs currently licensed by Health Canada for meno-
pause, in terms of frequently found active ingredients and
balance between single ingredient and multiple ingredient
products [29]. For example, the following active ingredi-
ents are commonly in Health Canada licensed menopause
NHPs: black cohosh (51%), chaste tree (36%), soy or red
clover isoflavones (20%); and 45% of the licensed NHPs in-
clude a single active ingredient [29].
The objective of our study is limited to the investiga-
tion of OTC NHPs in Canada-wide pharmacies only.
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(for example black cohosh), the products identified in
this research are not restricted to the selected pharmacy
chains and are likely available at independent pharma-
cies, naturopaths and herbalists. It is of note that many
NHPs advertised for menopausal symptoms (including
those identified in our study) can be bought outside of
pharmacies, for example by mail order or online.
While this study is specific to the NHPs available in
Canada, the use of NHPs in treating menopausal symp-
toms is not limited to Canada alone. Other investiga-
tions into the use of natural health therapies (black
cohosh, isoflavones, phytoestrogens, and others) to treat
the symptoms of menopause have been published
throughout the world, including in the United Kingdom,
Australia, Italy, and Turkey [30-33]. A brief informal
search of pharmacy websites in Europe, Australia and
USA found that Promensil® products and A.Vogel™ Sage,
as well as many generic products of black cohosh, soy
isoflavones, and chaste tree are widely available inter-
nationally. Therefore, our findings regarding the ingredi-
ents and doses of NHPs for menopause that are easily
accessible to Canadian women have relevance beyond
Canada.
Women are keen to make their own decisions about
the use of NHPs in menopause [7], largely because of
their concerns about perceived risks associated with hor-
mone replacement therapy [4-6]. Women must balance
the potential for benefit with the possible harm when
making NHP decisions however the quality and type of
evidence available to support women is often limited as
illustrated by our study. It is important that women are
aware that the regulation of these products does not
imply their effectiveness, as the evidence required by
Health Canada for licensing NHPs treating “low thera-
peutic impact conditions”, including menopause, reflects
“the low risk nature of these products” [10,11]. Evidence-
based decision aids designed to improve the quality of
decision-making are fairly common to support meno-
pausal women’s decisions about whether to use hormone
replacement therapy [34]. Unfortunately few studies of de-
cision aids regarding the use of NHPs have been under-
taken [35,36].
Over-the-counter NHPs are widely available for women
who wish to self-manage their menopausal symptoms. Fu-
ture directions for research in this area may include inves-
tigation into the high placebo response seen in controlled
trials of NHP supplements for menopausal symptoms, as
well as examining the efficacy and safety of combination
NHP supplements; most published scientific trials have
solely investigated single-ingredient supplements, though
almost half of the products identified in this study avail-
able for purchase were combination products. Adequately
designed decision aids would incorporate the evidencethat is available to support the use of NHPs as well as dis-
cussing the information that is unknown [34].
Conclusion
Women seeking non-hormonal treatments for their
menopause symptoms may prefer to use NHPs some-
times based on lay beliefs rather than evidence [37], in-
curring the potential of interaction with prescription
medications [38,39]. Our study found that NHPs for
menopausal symptoms are easily available in Canadian
pharmacies. The lack of clear evidence of product effi-
cacy, safety with respect to potential interactions with
prescribed medications, and cost comparisons poses a
challenge for women to make well-informed treatment
choices. Further information is needed about the factors
women take into account in making decisions about the
purchase of NHPs.
Abbreviations
NHP: Natural health product; NPN: Health Canada Natural Product Number;
OTC: Over-the-counter; SD: Standard deviation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JC participated in the design of the study, identified natural health products
in the pharmacies, collected, entered, tabulated and analyzed the data,
wrote the manuscript. SR participated in the design of the study, verified the
data on natural health products, and contributed to analysis and writing. NY
participated in the design of the study, provided expert pharmacist input,
and contributed to analysis and writing. BCS conceived of the idea for the
study, participated in the design and data collection, and contributed to
analysis and writing. All authors read and approved the final manuscript.
Acknowledgements
Jennifer Croden was financially supported by a University of Alberta
Women’s and Children’s Health Research Institute (WCHRI) summer student
award. Sue Ross is the Carvazan Chair of Mature Women’s Health Research.
Beate Sydora and Sue Ross are supported by funding from WCHRI.
Author details
1Department of Obstetrics and Gynecology, Faculty of Medicine and
Dentistry, University of Alberta, 5S131 Lois Hole Hospital for Women, Robbins
Pavilion, Royal Alexandra Hospital, 10240 Kingsway Avenue NW, Edmonton,
AB T5H 3 V9, Canada. 2Faculty of Pharmacy and Pharmaceutical Sciences,
3-171 Edmonton Clinic Health Academy, 11405 – 87 Avenue NW, Edmonton,
AB T6G 1C9, Canada.
Received: 21 November 2014 Accepted: 12 March 2015
References
1. Utian WH. Psychosocial and socioeconomic burden of vasomotor
symptoms in menopause: A comprehensive review. Health Qual Life
Outcomes. 2005;3:47.
2. Woods NF, Mitchell ES. Symptoms during the perimenopause: Prevalence,
severity, trajectory, and significance in women’s lives. Am J Med.
2005;2005(118):14–24.
3. McNagny SE. Prescribing hormone replacement therapy for menopausal
symptoms. Ann Intern Med. 1999;131:605–16.
4. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease,
and other considerations. Ann Rev Pub Health. 1998;19:55–72.
5. Stuenkel CA, Gass ML, Manson JE, Lobo RA, Pal L, Rebar RW, et al. A decade
after the Women’s Health Initiative - the experts do agree. Menopause.
2012;19:846–7.
Croden et al. BMC Complementary and Alternative Medicine  (2015) 15:86 Page 8 of 86. North American Menopause Society. Position statement: estrogen and
progestogen use in postmenopausal women. Menopause. 2008;15:584–603.
7. Légaré F, Stacey D, Dodin S, O'Connor A, Richer M, Griffiths F, et al.
Women’s decision making about the use of natural health products at
menopause: a needs assessment and patient decision aid. J Altern
Complement Med. 2007;13:741–49.
8. Lunny CA, Fraser SN. The use of complementary and alternative medicines
among a sample of Canadian menopausal-aged women. J Midwifery
Womens Health. 2010;55:335–43.
9. Wathen CN. Alternatives to hormone replacement therapy: a multi-method
study of women’s experiences. Complement Ther Med. 2006;14:185–92.
10. Health Canada. About Natural Health Product Regulation in Canada. [http://
www.hc-sc.gc.ca/dhp-mps/prodnatur/about-apropos/index-eng.php]
11. Smith A, Jogalekar S, Gibson A. Regulation of natural health products in
Canada. J Ethnopharmacol 2014, pii: S0378-8741 (14)00485-1. doi:10.1016/
j.jep.2014.06.037. [Epub ahead of print]
12. Kelley KW, Carroll DG. Evaluating the evidence for over-the-counter alternatives
for relief of hot flashes in menopausal women. J Am Pharm Assoc.
2003;50:e106–15.
13. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal
symptoms. Cochrane Database of Syst Rev. 2012;9:CD007244.
14. Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolff A.
Suspected black cohosh hepatotoxicity–challenges and pitfalls of causality
assessment. Maturitas. 2009;63(4):302–14.
15. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J.
Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database
of Syst Rev. 2013;12, CD001395.
16. Chen MN, Lin CC, Liu C. Efficacy of phytoestrogens for menopausal
symptoms: a meta-analysis and systematic review. Climacteric. 2014;29:1–21.
17. Laakmann E, Grajecki D, Doege K, zu Eulenburg C, Buhling KJ. Efficacy of
Cimicifuga racemosa, Hypericum perforatum and Agnus castus in the
treatment of climacteric complaints: a systematic review. Gynecol
Endocrinol. 2012;28:703–9.
18. Health Canada, Site Licensing. [http://www.hc-sc.gc.ca/dhp-mps/prodnatur/
applications/licen-site-exploit/index-eng.php] (accessed 23 February 2015)
19. Health Canada, Natural Health Products Compliance and Enforcement
Policy. [http://www.hc-sc.gc.ca/dhp-mps/compli-conform/info-prod/
prodnatur/complian-conform-pol-eng.php] (accessed 9 February 2015)
20. Boon HS, Kachan N. Natural health product labels: is more information
always better? Patient Educ Couns. 2007;68:193–9.
21. Braun LA, Tiralongo E, Wilkinson JM, Spitzer O, Bailey M, Poole S, et al.
Perceptions, use and attitudes of pharmacy customers on complementary
medicines and pharmacy practice. BMC Complement Altern Med.
2010;10:38.
22. Ismail R, Taylor-Swanson L, Thomas A, Schnall JG, Cray L, Mitchell ES, et al.
Effect of herbal preparations on symptom clustering during the menopausal
transition. Climacteric. 2015;18:11–28.
23. Shifren JL, Gass ML, NAMS Recommendations for Clinical Care of Midlife
Women Working Group. The North American Menopause Society
recommendations for clinical care of midlife women. Menopause.
2014;21(10):1038–62.
24. Murkies AL, Lombard C, Strauss BJ, Wilcox G, Burger HG, Morton MS. Dietary
flour supplementation decreases post-menopausal hot flushes: effect of soy
and wheat. Maturitas. 1995;21:189–95.
25. Baber RJ, Templeman C, Morton T, Kelly GE, West L. Randomized placebo-
controlled trial of an isoflavone supplement and menopausal symptoms in
women. Climacteric. 1999;2:85–92.
26. Tice JA, Ettinger B, Ensrud K, Wallace R, Blackwell T, Cummings SR.
Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone
Clover Extract (ICE) Study: a randomized controlled trial. JAMA.
2003;290:207–14.
27. Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y, Epstein G, et al.
Safety and efficacy of black cohosh and red clover for the management of
vasomotor symptoms: a randomized controlled trial. Menopause.
2009;16:1156–66.
28. Auerbach L, Rakus J, Bauer C, Gerner C, Ullmann R, Wimmer H, et al.
Pomegranate seed oil in women with menopausal symptoms: a
prospective randomized, placebo-controlled, double-blinded trial.
Menopause. 2012;19:426–32.29. Health Canada, Licensed Natural Health Product Database. [http://www.hc-
sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/lnhpd-bdpsnh-
eng.php] (accessed 29 October 2014)
30. Gokhale L, Sturdee DW, Parsons AD. The use of food supplements among
women attending menopause clinics in the West Midlands. Journal of the
British Menopause Society. 2003;9(1):32–5.
31. Gollschewski S, Anderson D, Skerman H, Lyons-Wall P. The use of complementary
and alternative medications by menopausal women in South East Queensland.
Womens Health Issues. 2004;14(5):165–71.
32. Cardini F, Lesi G, Lombardo F, van der Sluijs C. The use of Complementary
and Alternative Medicine by women experiencing menopausal symptoms
in Bologna. BMC Womens Health. 2010;10:7.
33. Koç Z, Saglam Z, Topatan S. Determination of the use of complementary
and alternative medicine by women in the climacteric period in the Turkish
city of Samsun. Contemp Nurse. 2013;45(2):197–209.
34. Carpenter JS, Studts JL, Byrne MM. A systematic review of menopausal
symptom management decision aid trials. Maturitas. 2011;69:11–21.
35. Légaré F, Dodin S, Stacey D, Leblanc A, Tapp S. Patient decision aid on
natural health products for menopausal symptoms: randomized controlled
trial. Menopause Int. 2008;14:105–10.
36. Menard P, Stacey D, Légare F, Woodend K. Evaluation of a natural health
product decision aid: a tool for middle aged women considering
menopausal symptom relief. Maturitas. 2010;65:366–71.
37. Gratus C, Wilson S, Greenfield SM, Damery SL, Warmington SA, Grieve R,
et al. The use of herbal medicines by people with cancer: a qualitative
study. BMC Complement Altern Med. 2009;14:9–14.
38. Vohra S, Cvijovic K, Boon H, Foster BC, Jaeger W, LeGatt D, et al. Study of
natural health product adverse reactions (SONAR): active surveillance of
adverse events following concurrent natural health product and prescription
drug use in community pharmacies. PLoS One. 2012;7(9):e45196.
39. Low Dog T, Marles R, Mahady G, Gardiner P, Ko R, Barnes J, et al. Assessing
safety of herbal products for menopausal complaints: An international
perspective. Maturitas. 2010;66:355–62.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
